JP2018500006A - 改変ｔ細胞における遺伝子発現の改変およびその使用 - Google Patents

改変ｔ細胞における遺伝子発現の改変およびその使用 Download PDF

Info

Publication number
JP2018500006A
JP2018500006A JP2017523296A JP2017523296A JP2018500006A JP 2018500006 A JP2018500006 A JP 2018500006A JP 2017523296 A JP2017523296 A JP 2017523296A JP 2017523296 A JP2017523296 A JP 2017523296A JP 2018500006 A JP2018500006 A JP 2018500006A
Authority
JP
Japan
Prior art keywords
cells
cell
tcr
modified
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017523296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500006A5 (enExample
Inventor
ヤンビン チャオ
ヤンビン チャオ
チアンタオ レン
チアンタオ レン
シャオジュン リュー
シャオジュン リュー
カール エイチ． ジューン
カール エイチ． ジューン
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018500006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2018500006A publication Critical patent/JP2018500006A/ja
Publication of JP2018500006A5 publication Critical patent/JP2018500006A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017523296A 2014-10-31 2015-10-15 改変ｔ細胞における遺伝子発現の改変およびその使用 Ceased JP2018500006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073651P 2014-10-31 2014-10-31
US62/073,651 2014-10-31
PCT/US2015/055780 WO2016069282A1 (en) 2014-10-31 2015-10-15 Altering gene expression in modified t cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2018500006A true JP2018500006A (ja) 2018-01-11
JP2018500006A5 JP2018500006A5 (enExample) 2018-11-22

Family

ID=55858177

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017523296A Ceased JP2018500006A (ja) 2014-10-31 2015-10-15 改変ｔ細胞における遺伝子発現の改変およびその使用
JP2017523279A Active JP6879910B2 (ja) 2014-10-31 2015-10-15 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2020208069A Active JP7792114B2 (ja) 2014-10-31 2020-12-16 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2023004286A Active JP7657474B2 (ja) 2014-10-31 2023-01-16 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2025043131A Pending JP2025089344A (ja) 2014-10-31 2025-03-18 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017523279A Active JP6879910B2 (ja) 2014-10-31 2015-10-15 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2020208069A Active JP7792114B2 (ja) 2014-10-31 2020-12-16 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2023004286A Active JP7657474B2 (ja) 2014-10-31 2023-01-16 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
JP2025043131A Pending JP2025089344A (ja) 2014-10-31 2025-03-18 Ｃａｒｔ細胞における遺伝子発現の改変およびその使用

Country Status (13)

Country Link
US (7) US20170335331A1 (enExample)
EP (4) EP3215168B1 (enExample)
JP (5) JP2018500006A (enExample)
KR (5) KR102546296B1 (enExample)
CN (3) CN107206024B (enExample)
AU (4) AU2015339743C1 (enExample)
BR (1) BR112017008693A2 (enExample)
CA (2) CA2964948A1 (enExample)
EA (1) EA201790953A1 (enExample)
ES (1) ES2983094T3 (enExample)
MX (2) MX2017005698A (enExample)
PL (1) PL3215166T3 (enExample)
WO (2) WO2016069282A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510657A (ja) * 2015-03-27 2018-04-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 改変ｔ細胞ならびにそれを作製および使用する方法
KR20210019993A (ko) * 2018-04-05 2021-02-23 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
JP2022512703A (ja) * 2018-10-16 2022-02-07 インテリア セラピューティクス，インコーポレイテッド 免疫療法のための組成物および方法
JP2022518463A (ja) * 2019-01-16 2022-03-15 ビーム セラピューティクス インク． 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
KR102073901B1 (ko) 2011-09-08 2020-02-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CN111471674A (zh) 2014-03-05 2020-07-31 国立大学法人神户大学 特异性转变靶向dna序列的核酸碱基的基因组序列的修饰方法、及其使用的分子复合体
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
ES2759260T3 (es) 2014-04-23 2020-05-08 Juno Therapeutics Inc Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
CN114231527A (zh) 2015-04-06 2022-03-25 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
CN108135938A (zh) 2015-07-16 2018-06-08 耶达研究及发展有限公司 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
AU2016333898B2 (en) 2015-10-05 2020-11-12 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
EP3680329B1 (en) 2015-10-05 2021-06-09 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
CN108495932B (zh) 2015-11-27 2022-08-09 国立大学法人神户大学 用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体
MA43380A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Récepteurs chimériques modifiés et compositions et procédés associés
CA3006432A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
AU2017292667A1 (en) * 2016-07-05 2019-02-21 The Johns Hopkins University Compositions and methods comprising improvements of CRISPR guide RNAs using the H1 promoter
US20200069818A1 (en) * 2016-07-05 2020-03-05 The Johns Hopkins University Crispr/cas9-based compositions and methods for treating cancer
CN106191062B (zh) * 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 一种tcr-/pd-1-双阴性t细胞及其构建方法
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
RU2767206C2 (ru) 2016-08-12 2022-03-16 Тулджен Инкорпорейтед Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106480097A (zh) * 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
CN106399375A (zh) * 2016-08-31 2017-02-15 南京凯地生物科技有限公司 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
MX2019003768A (es) * 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
GB2607227B (en) * 2016-10-27 2023-05-10 Intima Bioscience Inc Viral methods of T cell therapy
KR102614328B1 (ko) 2016-11-07 2023-12-14 제노비에 에이비 T-세포 수용체 합성 및 tcr-제시 세포에 대한 안정적인 게놈 통합을 위한 2-부분 디바이스
CA3038919A1 (en) * 2016-11-07 2018-05-11 Genovie Ab An engineered multi-component system for identification and characterisation of t-cell receptors, t-cell antigens and their functional interaction
JP7645606B2 (ja) 2016-11-07 2025-03-14 ジェノヴィー エービー Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11613574B2 (en) 2017-01-10 2023-03-28 The General Hospital Corporation Methods and compositions relating to ex vivo culture and modulation of T cells
US12459975B2 (en) 2017-01-10 2025-11-04 The General Hospital Corporation Modified T cells and methods of their use
IL268126B2 (en) * 2017-01-18 2024-02-01 Yeda Res & Dev Genetically engineered Veto cells and their uses in immunotherapy
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CN110913690A (zh) * 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
SG11201907434RA (en) * 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018191490A1 (en) 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
JP7292213B2 (ja) * 2017-05-04 2023-06-16 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法
JP7235391B2 (ja) 2017-05-08 2023-03-08 ツールゲン インコーポレイテッド 人工的に操作された免疫細胞
JP7170666B2 (ja) * 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ，インク． 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110944652A (zh) * 2017-06-12 2020-03-31 爱莫里大学 T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
KR20240027153A (ko) 2017-06-15 2024-02-29 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 비-바이러스 dna 삽입
US20200181608A1 (en) * 2017-06-20 2020-06-11 Jiangsu Hengrui Medicine Co., Ltd. METHOD FOR KNOCKING OUT TARGET GENE IN T CELL IN VITRO AND crRNA USED IN THE METHOD
WO2018236909A1 (en) * 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US11053484B2 (en) 2017-06-30 2021-07-06 Precision Biosciences, Inc. Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
WO2019047932A1 (zh) * 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
US20200216805A1 (en) * 2017-09-18 2020-07-09 Edigene Inc. Gene editing t cell and use thereof
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
CN109517820B (zh) * 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
CN107630006B (zh) * 2017-09-30 2020-09-11 山东兴瑞生物科技有限公司 一种制备tcr与hla双基因敲除的t细胞的方法
MX2020003536A (es) * 2017-10-03 2020-09-14 Juno Therapeutics Inc Moleculas de union especifica a virus de papiloma humano (hpv).
JP7333495B2 (ja) 2017-10-10 2023-08-25 国立大学法人広島大学 エフェクターＴ細胞（Ｔｅｆｆ）抗原受容体を用いた抗原特異的制御性Ｔ細胞（Ｔｒｅｇ）の作出技術
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
EP3702453A4 (en) * 2017-10-10 2021-07-21 Hiroshima University TOTAL REPLACEMENT TECHNIQUE FOR T-LYMPHOCYTE RECEPTOR USING PLATINUM TALENE
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN107827989A (zh) * 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
MY201694A (en) 2017-10-27 2024-03-13 Univ California Targeted replacement of endogenous t cell receptors
TWI716758B (zh) 2017-10-30 2021-01-21 美商Ｐａｃｔ製藥公司 初代細胞基因編輯
CN107916269B (zh) * 2017-11-17 2020-12-11 山东兴瑞生物科技有限公司 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
WO2019106163A1 (en) * 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
EP3724326A1 (en) * 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
CN111479917A (zh) * 2017-12-13 2020-07-31 詹森生物科技公司 经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CA3086267A1 (en) * 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CN108559760A (zh) * 2018-01-09 2018-09-21 陕西师范大学 基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
EP3737765B2 (en) 2018-01-12 2025-01-22 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
US12215154B2 (en) 2018-01-19 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting γδ T cells with chimeric antigen receptors
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
WO2019157454A1 (en) * 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
CN119851752A (zh) 2018-02-27 2025-04-18 磨石生物公司 利用泛等位基因模型进行的新抗原鉴别
US10780120B2 (en) 2018-03-06 2020-09-22 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN118325839A (zh) 2018-03-27 2024-07-12 宾夕法尼亚大学董事会 具有增强功能的修饰的免疫细胞及其筛选方法
CA3133899A1 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
WO2019195310A1 (en) 2018-04-02 2019-10-10 Pact Pharma, Inc. Peptide-mhc compacts
JP7589047B2 (ja) 2018-04-05 2024-11-25 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
KR20210020873A (ko) 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
IL317539A (en) 2018-04-12 2025-02-01 Prec Biosciences Inc Optimized engineered nucleases with specificity for the human T-cell receptor alpha constant region gene
CN108490174B (zh) * 2018-04-18 2022-06-24 上海尚珞生物医药科技有限公司 检测car-t细胞的方法及其应用
BR112020021685A2 (pt) * 2018-04-26 2021-01-26 Baylor College Of Medicine receptores de defesa auto/aloimune para o direcionamento seletivo de células t e células nk patogênicas ativadas
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CA3101505A1 (en) * 2018-05-31 2019-12-05 Washington University Chimeric antigen receptor t cells (car-t) for the treatment of cancer
EP3801574A4 (en) * 2018-05-31 2022-03-16 Washington University METHODS FOR GENOMIC EDITING AND CELL ACTIVATION
CN110616188B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种通用型car-t细胞及其制备方法和应用
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
EP3833743B1 (en) * 2018-08-08 2024-01-24 NantBio, Inc. Recombinant cd1-restricted t cells for treating tuberculosis
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
US20220017926A1 (en) * 2018-09-21 2022-01-20 Cafa Therapeutics Limited Method for gene editing of cell on the basis of crispr/cas system
EP3868887A4 (en) * 2018-09-25 2022-12-07 Microbial Chemistry Research Foundation NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
CN109295106B (zh) * 2018-09-30 2020-07-24 北京鼎成肽源生物技术有限公司 一种hafft1细胞
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
EP3877421A1 (en) * 2018-11-07 2021-09-15 CRISPR Therapeutics AG Anti-ptk7 immune cell cancer therapy
US12304968B2 (en) * 2018-11-07 2025-05-20 Crispr Therapeutics Ag T-cells expressing anti-LIV1 chimeric antigen receptor
EP3877414A1 (en) * 2018-11-07 2021-09-15 CRISPR Therapeutics AG Anti-cd33 immune cell cancer therapy
WO2020103013A1 (en) * 2018-11-21 2020-05-28 Nanjing Bioheng Biotech Co., Ltd Modified t cells and uses thereof
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
CN109722437B (zh) * 2018-12-29 2020-01-07 广州百暨基因科技有限公司 一种通用型car-t细胞及其制备方法和用途
CN109652378B (zh) * 2018-12-29 2020-04-24 广州百暨基因科技有限公司 一种功能增强的通用型car-t细胞及其制备方法和用途
CN121243425A (zh) 2019-01-18 2026-01-02 奥泽生物疗法公司 基因编辑以改善关节功能
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7611836B2 (ja) 2019-02-12 2025-01-10 パクト ファーマ インコーポレイテッド 抗原特異的ｔ細胞の同定のための組成物と方法
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020168392A1 (en) 2019-02-22 2020-08-27 Garvan Institute Of Medical Research Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject
CN109913501B (zh) * 2019-03-01 2022-08-16 华东师范大学 一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
US12473346B2 (en) 2019-03-18 2025-11-18 Ludwig Institute For Cancer Research Ltd A2/NY-ESO-1 specific t cell receptors and uses thereof
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
ES3036043T3 (en) * 2019-03-21 2025-09-12 Allogene Therapeutics Inc Methods for enhancing tcr alpha beta+ cell depletion efficiency
MX2021012110A (es) 2019-04-03 2022-01-06 Prec Biosciences Inc Celulas inmunitarias geneticamente modificadas que comprenden un arnhc adaptado a microarn (arnhcmir).
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3962535A1 (en) 2019-04-30 2022-03-09 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN112430575B (zh) * 2019-08-26 2024-01-19 深圳市菲鹏生物治疗股份有限公司 通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
AU2020343516A1 (en) 2019-09-06 2022-03-10 Crispr Therapeutics Ag Genetically engineered T cells having improved persistence in culture
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CA3155667A1 (en) * 2019-09-27 2021-04-01 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023501617A (ja) * 2019-11-13 2023-01-18 クリスパー セラピューティクス アクチェンゲゼルシャフト Ｃａｒ－ｔ細胞を製造する方法
US20210139850A1 (en) * 2019-11-13 2021-05-13 Crispr Therapeutics Ag Manufacturing process for making t cells expressing chimeric antigen receptors
EP4061927A4 (en) * 2019-11-20 2024-11-13 Cartherics Pty. Ltd. METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
WO2021108557A1 (en) * 2019-11-27 2021-06-03 Stitch Bio, Llc Methods and compositions for inducing tumor cell death
WO2021136263A1 (zh) * 2020-01-02 2021-07-08 江苏茂行科技有限公司 一种经修饰的免疫效应细胞及其制备方法
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN114929867A (zh) * 2020-01-21 2022-08-19 苏州克睿基因生物科技有限公司 一种经修饰的免疫效应细胞及其用途
US20210254005A1 (en) * 2020-01-23 2021-08-19 Kangstem Biotech Co., Ltd. Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
JP2023515270A (ja) * 2020-04-21 2023-04-12 テンパス・ラボズ・インコーポレイテッド Ｔｃｒ／ｂｃｒプロファイリング
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
EP4171587A4 (en) * 2020-06-25 2024-07-24 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
WO2022012531A1 (zh) * 2020-07-14 2022-01-20 苏州克睿基因生物科技有限公司 一种经修饰的免疫细胞的制备方法
KR20230011959A (ko) * 2020-07-15 2023-01-25 난징 바이오흐엥 바이오테크 씨오., 엘티디 동종이계 이식을 위한 조작된 면역 세포
BR112023000738A2 (pt) * 2020-07-16 2023-03-21 Orthobio Therapeutics Inc Composições farmacêuticas, métodos para o tratamento ou prevenção de uma doença, tratar claudicação canina, tratar claudicação equina, inativar uma il-1a ou il-1ss endógena e reduzir a expressão do gene il-1a ou il-1ss, método de tratamento de um indivíduo com artrite, doença articular e osteoartrite, método mediado por crispr/cas9 para tratamento de doenças articulares, nuclease crisprcas, repetições palindrômicas, sistema vetorial e método de alteração de uma sequência de ácido nucleico
JP7634653B2 (ja) * 2020-08-20 2025-02-21 エー２ バイオセラピューティクス， インコーポレイテッド メソテリン陽性がんを治療するための組成物及び方法
IL302063A (en) * 2020-10-13 2023-06-01 Univ Pennsylvania Designation of intracorporeal t cells for messenger RNA medicine
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
WO2022106731A1 (en) * 2020-11-23 2022-05-27 Ludwig-Maximilians-Universität München Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN112899227B (zh) * 2021-01-14 2022-09-13 中国科学院微生物研究所 一种调控辅助性t细胞功能的方法
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN116964083A (zh) * 2021-03-04 2023-10-27 艾洛基治疗公司 用于保护治疗性细胞免于发生同种异体排斥和激活诱导的细胞死亡的FasL表达和FasR基因敲除
CN117413054A (zh) * 2021-03-08 2024-01-16 宾夕法尼亚大学董事会 评估和治疗t细胞功能障碍的组合物和方法
CA3230927A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023055942A1 (en) * 2021-09-29 2023-04-06 The Johns Hopkins University Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4416292A2 (en) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN113980907B (zh) * 2021-12-24 2022-03-15 山东兴瑞生物科技有限公司 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
CN114591963B (zh) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA及利用其构建GM-CSF(-)细胞的方法
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
KR20250069905A (ko) * 2022-09-19 2025-05-20 에멘도바이오 인코포레이티드 Pdcd1의 이중 대립유전자 녹아웃
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CA3267005A1 (en) * 2022-12-09 2024-06-13 Research Institute At Nationwide Children's Hospital Chimeric Antigen Receptor (CAR) T Lymphocytes and Their Uses
EP4630014A1 (en) * 2022-12-09 2025-10-15 CeMM - Forschungszentrum für Molekulare Medizin GmbH Method for optimizing t cells for immuno-therapy
AU2024214593A1 (en) 2023-02-03 2025-08-07 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024165053A1 (zh) * 2023-02-10 2024-08-15 南京北恒生物科技有限公司 功能增强的细胞疗法
AU2024233625A1 (en) 2023-03-03 2025-09-18 Arsenal Biosciences, Inc. Systems targeting psma and ca9
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP2013535215A (ja) * 2010-08-04 2013-09-12 ステムバイオス テクノロジーズ，インコーポレイテッド 体性幹細胞
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2013158292A1 (en) * 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014153470A2 (en) * 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
JP2017535261A (ja) * 2014-10-31 2017-11-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA120409A (en) 1909-05-13 1909-09-07 Hiram Lucas Piper Signal lamp
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
AU678843B2 (en) 1993-08-10 1997-06-12 W.L. Gore & Associates, Inc. Cell encapsulating device
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6143291A (en) 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
AU6251196A (en) 1995-06-07 1996-12-30 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical dev ice and method for loading and reloading the device therein
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EP0970126B1 (en) 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
KR20080086983A (ko) 2005-12-07 2008-09-29 제네트로닉스, 인코포레이티드 가변 부피의 전기천공 챔버 및 이의 사용 방법
WO2007150054A2 (en) 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
EP2537416B1 (en) 2007-03-30 2014-11-12 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CN101854949A (zh) 2007-08-30 2010-10-06 健泰科生物技术公司 用于调控t细胞的方法和组合物
CN105802917A (zh) * 2008-10-24 2016-07-27 威斯康星校友研究基金会 通过非病毒重编程获得的多潜能干细胞
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) * 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN117756916A (zh) 2010-09-20 2024-03-26 生物技术细胞和基因治疗公司 抗原特异性t细胞受体和t细胞表位
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
DK2699593T4 (da) * 2011-04-20 2021-02-08 Univ Washington Through Its Center For Commercialization Beta-2 mikroglobulin-deficiente celler
ES2888651T3 (es) * 2011-07-29 2022-01-05 Univ Pennsylvania Receptores de conmutación coestimulantes
US10040846B2 (en) * 2012-02-22 2018-08-07 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
PT2852613T (pt) 2012-05-22 2019-05-20 Us Health Recetores de célula t anti-ny-eso-1 murinos
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
EP4570908A3 (en) 2012-05-25 2025-10-22 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
CN104769103B (zh) * 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10544405B2 (en) 2013-01-16 2020-01-28 Emory University Cas9-nucleic acid complexes and uses related thereto
CN105283539A (zh) * 2013-03-12 2016-01-27 桑格摩生物科学股份有限公司 用于hla的修饰的方法和组合物
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US9587237B2 (en) * 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
US9873894B2 (en) * 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
EP3004337B1 (en) * 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
TR201819571T4 (tr) 2014-02-14 2019-01-21 Cellectis Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler.
ES2782125T3 (es) * 2014-03-11 2020-09-10 Cellectis Método para generar linfocitos T compatibles para trasplante alogénico
JP6788573B6 (ja) 2014-04-10 2020-12-16 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
EP3129473B8 (en) 2014-04-11 2020-12-23 Cellectis Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
KR102827558B1 (ko) 2014-04-18 2025-07-11 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
US10201597B2 (en) 2014-09-30 2019-02-12 The Regents Of The University Of California Codon-optimized lentiviral vector for stem cell reprogramming
EP3204399B1 (en) * 2014-10-09 2025-01-22 Seattle Children's Hospital, dba Seattle Children's Research Institute Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EP3273976B1 (en) * 2015-03-27 2023-07-26 President and Fellows of Harvard College Modified t cells and methods of making and using the same
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
JP2013535215A (ja) * 2010-08-04 2013-09-12 ステムバイオス テクノロジーズ，インコーポレイテッド 体性幹細胞
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013158292A1 (en) * 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
WO2013176915A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014153470A2 (en) * 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
JP2017535261A (ja) * 2014-10-31 2017-11-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG DELIVERY SYSTEM, vol. 28, no. 1, JPN6019046052, 2013, pages 35 - 44, ISSN: 0004534276 *
JOURNAL OF GENERAL VIROLOGY, vol. 96, JPN6019046054, 2015, pages 2381 - 2393, ISSN: 0004534275 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510657A (ja) * 2015-03-27 2018-04-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 改変ｔ細胞ならびにそれを作製および使用する方法
KR20210019993A (ko) * 2018-04-05 2021-02-23 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
JP2021520198A (ja) * 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞受容体およびそれを発現する操作された細胞
JP7410868B2 (ja) 2018-04-05 2024-01-10 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞受容体およびそれを発現する操作された細胞
KR102764123B1 (ko) 2018-04-05 2025-02-05 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포
JP2022512703A (ja) * 2018-10-16 2022-02-07 インテリア セラピューティクス，インコーポレイテッド 免疫療法のための組成物および方法
JP2022518463A (ja) * 2019-01-16 2022-03-15 ビーム セラピューティクス インク． 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Also Published As

Publication number Publication date
AU2021203981A1 (en) 2021-07-15
EP3215166B1 (en) 2024-04-24
HK1243332A1 (en) 2018-07-13
US20200407728A1 (en) 2020-12-31
AU2021200118B2 (en) 2023-09-21
CA2964948A1 (en) 2016-05-06
AU2024203330A1 (en) 2024-08-08
CA2964953A1 (en) 2016-05-06
EP4219725A2 (en) 2023-08-02
WO2016069282A1 (en) 2016-05-06
EP4219725A3 (en) 2023-08-30
EP3215166A4 (en) 2018-12-05
US20170335331A1 (en) 2017-11-23
JP2021058196A (ja) 2021-04-15
US12344843B2 (en) 2025-07-01
AU2015339743A1 (en) 2017-04-27
EP3215168A4 (en) 2018-08-15
US11203758B2 (en) 2021-12-21
EP3215168B1 (en) 2023-08-02
EP4427809A3 (en) 2024-12-04
KR102546296B1 (ko) 2023-06-21
US20220145306A1 (en) 2022-05-12
JP7792114B2 (ja) 2025-12-25
WO2016069283A1 (en) 2016-05-06
JP2023037006A (ja) 2023-03-14
JP7657474B2 (ja) 2025-04-07
EP3215166A1 (en) 2017-09-13
EP4427809A2 (en) 2024-09-11
EP3215168A1 (en) 2017-09-13
KR102781429B1 (ko) 2025-03-18
BR112017008693A2 (pt) 2018-02-27
EP3215166B9 (en) 2024-11-27
AU2015339743B2 (en) 2020-11-05
CN107206024A (zh) 2017-09-26
AU2015339744B2 (en) 2021-03-25
ES2983094T3 (es) 2024-10-21
MX2017005698A (es) 2017-06-29
JP2017535261A (ja) 2017-11-30
US20220154190A1 (en) 2022-05-19
KR20170075013A (ko) 2017-06-30
CN107206024B (zh) 2021-12-03
US11208661B2 (en) 2021-12-28
EA201790953A1 (ru) 2017-10-31
KR20250005477A (ko) 2025-01-09
JP6879910B2 (ja) 2021-06-02
US20180312848A1 (en) 2018-11-01
US20170290858A1 (en) 2017-10-12
CN107249606A (zh) 2017-10-13
AU2015339743C1 (en) 2021-04-22
JP2025089344A (ja) 2025-06-12
US20240279665A1 (en) 2024-08-22
KR20230098910A (ko) 2023-07-04
KR20240075936A (ko) 2024-05-29
CN114836385B (zh) 2025-04-04
CN114836385A (zh) 2022-08-02
AU2015339744A1 (en) 2017-04-27
AU2021200118A1 (en) 2021-03-25
MX2023004169A (es) 2023-05-03
PL3215166T3 (pl) 2024-08-26
KR20170074245A (ko) 2017-06-29

Similar Documents

Publication Publication Date Title
JP7657474B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
US20260043032A1 (en) Altering gene expression in cart cells and uses thereof
HK40112241A (en) Altering gene expression in car-t cells and uses thereof
HK1243332B (en) Altering gene expression in modified t cells and uses thereof
EA040572B1 (ru) Изменение экспрессии гена в cart-клетках и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211101

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220217